JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Transcutaneous Spinal Stimulation: Safety and Feasibility for Trunk Control in Children With Spinal Cord Injury

  NCT03975634

  Condition:   Spinal Cord Injuries
  Intervention:   Device: Transcutaneous Spinal Stimulation
  Sponsors:   University of Louisville;   National Center of Neuromodulation for Rehabilitation (NM4R)
  Recruiting
• Using Media to Shift Social Norms of Violence Among Youth

  NCT02706145

  Condition:   Violence
  Intervention:   Other: Social norming campaign
  Sponsors:   University of Louisville;   Centers for Disease Control and Prevention;   Vanderbilt University
  Recruiting
• Adrenergic Cholinergic Enteric Measures/Mapping

  NCT04013282

  Condition:   Obesity
  Intervention:  
  Sponsor:   University of Louisville
  Recruiting
• PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)

  NCT03709914

  Condition:   Pediatric ALL
  Interventions:   Drug: ZTI-01 100 mg/kg;   Drug: ZTI-01 75 mg/kg
  Sponsor:   Nabriva Therapeutics AG
  Recruiting
• Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

  NCT03673462

  Condition:   Healthy Volunteers (Meningococcal Infection)
  Interventions:   Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine (MenACYW conjugate vaccine);   Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®);   Biological: Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Biological: Rotavirus Vaccine;   Biological: Hepatitis B Vaccine;   Biological: Measles, Mumps, and Rubella Virus Vaccine;   Biological: Varicella Virus Vaccine
  Sponsor:   Sanofi Pasteur, a Sanofi Company
  Recruiting
• Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

  NCT03636906

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Biological: Respiratory syncytial virus (RSV) vaccine GSK3389245A;   Biological: Bexsero;   Biological: Nimenrix;   Biological: Menveo;   Biological: Synflorix;   Drug: Placebo
  Sponsor:   GlaxoSmithKline
  Recruiting
• Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

  NCT03691610

  Condition:   Healthy Volunteers (Meningococcal Infection)
  Interventions:   Biological: Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine;   Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine;   Biological: Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine;   Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine;   Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine;   Biological: Haemophilus b Conjugate Vaccine;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Biological: Rotavirus Vaccine, Live, Oral, Pentavalent;   Biological: Hepatitis B Vaccine;   Biological: Measles, Mumps, and Rubella Virus Vaccine Live;   Biological: Varicella Virus Vaccine Live
  Sponsor:   Sanofi Pasteur, a Sanofi Company
  Recruiting
• Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

  NCT03537508

  Condition:   Meningococcal Infections
  Interventions:   Biological: MenACYW conjugate vaccine;   Biological: MenACYW-135 conjugate vaccine;   Biological: DTaP-IPV//Hib vaccine;   Biological: Pneumococcal 13-valent conjugate vaccine;   Biological: Pentavalent rotavirus vaccine;   Biological: Hepatitis B vaccine;   Biological: Measles, mumps, rubella (MMR) vaccine;   Biological: Varicella vaccine;   Biological: Hepatitis A vaccine
  Sponsor:   Sanofi Pasteur, a Sanofi Company
  Recruiting
• Dextromethorphan Pediatric Acute Cough Study

  NCT02651116

  Condition:   Cough
  Interventions:   Drug: Dextromethorphan Hydrobromide;   Drug: Placebo;   Device: Cough recording device
  Sponsor:   Pfizer
  Recruiting
• A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

  NCT01146990

  Condition:   Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial
  Intervention:   Drug: ASQ-3, Bayley III, Neurologic exam
  Sponsors:   AMAG Pharmaceuticals, Inc.;   Registrat-Mapi
  Recruiting
• Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181

  Conditions:   Adult Germ Cell Tumor;   Childhood Extracranial Germ Cell Tumor;   Childhood Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Grade 2 Ovarian Teratoma;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

  NCT03204916

  Condition:   Acute Lymphoblastic Leukemia
  Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680

  Conditions:   Solid Tumors;   Ewing Sarcoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Neuroblastoma;   Medulloblastoma;   Diffuse Intrinsic Pontine Glioma
  Interventions:   Drug: Palbociclib;   Drug: Temozolomide;   Drug: Irinotecan
  Sponsor:   Pfizer
  Recruiting
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

  NCT03725007

  Condition:   Juvenile Idiopathic Arthritis (JIA)
  Intervention:   Drug: Upadacitinib
  Sponsor:   AbbVie
  Recruiting
• A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

  NCT03988439

  Condition:   Psoriasis
  Intervention:   Drug: IDP-118 Lotion
  Sponsor:   Bausch Health Americas, Inc.
  Recruiting
• Asymptomatic Congenital CMV Treatment

  NCT03301415

  Condition:   Congenital Cytomegalovirus Infection
  Intervention:   Drug: Valganciclovir
  Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children

  NCT02891915

  Condition:   Pneumonia
  Interventions:   Drug: Amoxicillin;   Drug: Amoxicillin-clavulanate;   Drug: Cefdinir;   Other: Placebo
  Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• Study of Pediatric Migraine: The Pediatric Migraine Registry

  NCT03742024

  Condition:   Migraine
  Intervention:  
  Sponsors:   Duke University;   University of California, San Francisco
  Recruiting
• Vitamin D Supplementation in Children With Obesity-Related Asthma

  NCT03686150

  Conditions:   Asthma;   Vitamin D Deficiency;   Pediatric Obesity
  Intervention:   Dietary Supplement: Vitamin D3 oral regimen
  Sponsor:   IDeA States Pediatric Clinical Trials Network
  Recruiting
• Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

  NCT04074928

  Condition:   Influenza, Human
  Interventions:   Biological: QIVc;   Biological: Comparator QIV
  Sponsor:   Seqirus
  Recruiting
• A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants

  NCT03979313

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Drug: MEDI8897;   Drug: Placebo
  Sponsor:   MedImmune LLC
  Recruiting
• A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

  NCT03959488

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Drug: MEDI8897;   Drug: Palivizumab
  Sponsor:   MedImmune LLC
  Recruiting
• JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

  NCT03796676

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Placebo;   Drug: PF-04965842;   Drug: PF04965842
  Sponsor:   Pfizer
  Recruiting
• OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

  NCT03747458

  Condition:   Bilateral Nasal Polyposis
  Intervention:   Drug: OPN-375
  Sponsor:   Optinose US Inc.
  Recruiting
• A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

  NCT03692871

  Condition:   Pneumococcal Infections
  Interventions:   Biological: V114;   Biological: Prevnar 13™
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

  NCT02527681

  Condition:   Bacterial Infections
  Intervention:   Drug: ceftobiprole
  Sponsor:   Basilea Pharmaceutica
  Recruiting
• A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome

  NCT03571256

  Condition:   Tourette Syndrome
  Interventions:   Drug: deutetrabenazine Low;   Drug: deutetrabenazine High;   Drug: Placebo
  Sponsors:   Teva Branded Pharmaceutical Products, R&D Inc.;   Nuvelution TS Pharma, Inc.
  Recruiting
• Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

  NCT03550313

  Condition:   Pneumococcal Infections
  Interventions:   Biological: Multivalent;   Biological: Prevnar 13
  Sponsor:   Pfizer
  Recruiting
• Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

  NCT03526861

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Tralokinumab;   Drug: Placebos
  Sponsor:   LEO Pharma
  Recruiting
• Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

  NCT03429543

  Condition:   Diabetes Mellitus, Type 2
  Interventions:   Drug: Linagliptin;   Drug: Empagliflozin;   Drug: Placebo
  Sponsor:   Boehringer Ingelheim
  Recruiting
• Stress Hydrocortisone In Pediatric Septic Shock

  NCT03401398

  Condition:   Septic Shock
  Interventions:   Drug: Hydrocortisone, sodium succinate;   Drug: Normal saline
  Sponsors:   Jerry Zimmerman;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Canadian Institutes of Health Research (CIHR);   Canadian Critical Care Trials Group;   Children's Hospital of Eastern Ontario
  Recruiting
• Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

  NCT03275922

  Condition:   Migraine
  Interventions:   Drug: Placebo ZNS;   Drug: ZNS
  Sponsors:   Impax Laboratories, LLC;   AstraZeneca
  Recruiting
• Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission

  NCT03223753

  Condition:   Acute Lymphoblastic Leukemia in Remission
  Interventions:   Other: Educational Intervention;   Other: Internet-Based Intervention;   Other: Laboratory Biomarker Analysis;   Device: Monitoring Device;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

  NCT02852031

  Condition:   Hypoplastic Left Heart Syndrome (HLHS)
  Intervention:   Other: Collaborative Learning Network
  Sponsor:   Children's Hospital Medical Center, Cincinnati
  Recruiting
• Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358

  Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
  Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

  NCT02678312

  Condition:   Pediatric Heart Failure
  Interventions:   Drug: LCZ696;   Drug: Enalapril;   Drug: Placebo of LCZ696;   Drug: Placebo of Enalapril
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

  NCT02521493

  Conditions:   Acute Myeloid Leukemia;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Cytopenia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm;   Trisomy 21;   Trisomy 21 Mosaicism
  Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

  NCT02369653

  Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
  Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
  Sponsors:   Bristol-Myers Squibb;   Pfizer
  Recruiting
• Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

  NCT02176967

  Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
  Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

  NCT03907488

  Conditions:   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IIIA Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Classic Hodgkin Lymphoma;   Lymphocyte-Rich Classic Hodgkin Lymphoma
  Interventions:   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Biological: Nivolumab;   Biological: Pegfilgrastim;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Vinblastine;   Drug: Vinblastine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296

  Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Intervention:   Drug: Rucaparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

  NCT03627767

  Conditions:   Dermatitis;   Dermatitis, Atopic;   Eczema;   Skin Diseases;   Skin Diseases, Genetic;   Genetic Diseases, Inborn;   Skin Diseases, Eczematous;   Hypersensitivity;   Hypersensitivity, Immediate;   Immune System Diseases
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• Axitinib and Nivolumab in Treating Patients With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma

  NCT03595124

  Conditions:   Metastatic Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Unresectable Renal Cell Carcinoma
  Interventions:   Drug: Axitinib;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study in Children With Hyperkalaemia Between Birth and <18 Years of Age to Evaluate Doses of Sodium Zirconium Cyclosilicate (SZC) for Correction of Hyperkalaemia and Effectiveness of Same Dose to Maintain Normokalaemia.

  NCT03813407

  Condition:   Hyperkalaemia
  Interventions:   Drug: Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level;   Drug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1);   Drug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2);   Drug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3);   Drug: Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase
  Sponsor:   AstraZeneca
  Recruiting
• Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia

  NCT03268421

  Conditions:   Fibromyalgia;   Myofascial Pain Syndrome;   Muscular Diseases;   Musculoskeletal Disease;   Rheumatic Diseases
  Interventions:   Behavioral: Fibromyalgia Integrative Training for Teens;   Behavioral: Cognitive Behavioral Therapy;   Behavioral: Graded Aerobic Exercise
  Sponsors:   Children's Hospital Medical Center, Cincinnati;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  Recruiting
• TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

  NCT03745651

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Ruxolitinib cream;   Drug: Vehicle cream
  Sponsor:   Incyte Corporation
  Recruiting
• Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

  NCT02392078

  Conditions:   Metastatic Brain Tumor;   Primary Brain Tumor;   Epileptic/Seizure Foci
  Intervention:   Device: NeuroBlate System
  Sponsor:   Monteris Medical
  Recruiting
• Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

  NCT03533582

  Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Elevated Alpha-Fetoprotein;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

  NCT03233204

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   Wilms Tumor
  Intervention:   Drug: Olaparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

  NCT03220035

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Safety and Efficacy of 2 Treatment Regimens of Aztreonam for Inhalation Solution in Children With Cystic Fibrosis and New Onset Pseudomonas Aeruginosa Infection

  NCT03219164

  Conditions:   Pseudomonas Aeruginosa Respiratory Tract Infection;   Cystic Fibrosis
  Interventions:   Drug: AZLI;   Drug: Placebo
  Sponsor:   Gilead Sciences
  Recruiting
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

  NCT03213704

  Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Rhabdoid Tumor;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Wilms Tumor
  Interventions:   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213678

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Samotolisib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213665

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   EZH2 Gene Mutation;   Low Grade Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Hodgkin Lymphoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Hodgkin Lymphoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   SMARCA4 Gene Inactivation;   SMARCB1 Gene Inactivation;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Tazemetostat
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

  NCT03213652

  Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation
  Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03210714

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
  Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

  NCT03155620

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
  Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

  NCT03057626

  Conditions:   Recurrent Neuroblastoma;   Stage 2A Neuroblastoma;   Stage 2B Neuroblastoma;   Stage 3 Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147

  Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
  Recruiting
• A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

  NCT02927769

  Condition:   Hodgkin Disease
  Interventions:   Biological: Nivolumab;   Biological: brentuximab vedotin;   Biological: bendamustine
  Sponsors:   Bristol-Myers Squibb;   Seattle Genetics, Inc.
  Recruiting
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

  NCT02867592

  Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Neuroblastoma Maintenance Therapy Trial

  NCT02679144

  Condition:   Neuroblastoma
  Intervention:   Drug: Difluoromethylornithine (DFMO)
  Sponsors:   Giselle Sholler;   KC Pharma;   Beat NB Cancer Foundation
  Recruiting
• Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435

  Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
  Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

  NCT02559778

  Condition:   Neuroblastoma
  Interventions:   Drug: Ceritinib;   Drug: dasatinib;   Drug: sorafenib;   Drug: vorinostat;   Drug: DFMO
  Sponsors:   Giselle Sholler;   Dell, Inc.;   Beat NB Cancer Foundation
  Recruiting
• Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

  NCT02303431

  Conditions:   Deep Vein Thrombosis;   Venous Thromboembolism
  Interventions:   Drug: Edoxaban low dose;   Drug: Edoxaban high dose
  Sponsor:   Daiichi Sankyo, Inc.
  Recruiting
• LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

  NCT02205762

  Condition:   Langerhans Cell Histiocytosis
  Interventions:   Drug: Prednisone;   Drug: Vinblastine;   Drug: mercaptopurine;   Drug: INDOMETHACIN;   Drug: Methotrexate;   Drug: Cytosine Arabinoside;   Drug: 2-chlorodeoxyadenosine;   Procedure: hematopoietic stem cell transplantation (RIC-HSCT);   Biological: Intravenous immunoglobulin
  Sponsors:   North American Consortium for Histiocytosis;   Histiocyte Society
  Recruiting
• Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic Disorder

  NCT01707394

  Condition:   Thromboembolism
  Intervention:   Drug: Apixaban
  Sponsors:   Bristol-Myers Squibb;   Pfizer
  Recruiting
• Evaluation of the Duration of Therapy for Thrombosis in Children

  NCT00687882

  Condition:   Venous Thrombosis
  Interventions:   Other: Shortened duration (6 weeks) of anticoagulant therapy;   Other: Conventional duration (3 months) of anticoagulant therapy;   Other: No Intervention
  Sponsors:   Johns Hopkins All Children's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• A Prospective Observational Study of TPIAT

  NCT03260387

  Conditions:   Pancreatitis, Chronic;   Pancreatectomy; Hyperglycemia;   Pancreatitis
  Intervention:   Procedure: TPIAT
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Baylor Health Care System;   Medical University of South Carolina;   University of Chicago;   University of Pittsburgh Medical Center;   Dartmouth-Hitchcock Medical Center;   Johns Hopkins University;   Children's Hospital Medical Center, Cincinnati;   Ohio State University
  Recruiting
• A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

  NCT03539601

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Crisaborole ointment, 2%;   Drug: Hydrocortisone butyrate cream, 0.1%;   Drug: Pimecrolimus cream, 1%;   Drug: Crisaborole Vehicle
  Sponsor:   Pfizer
  Recruiting
• A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

  NCT04104685

  Condition:   Acne Vulgaris
  Interventions:   Combination Product: FCD105;   Drug: 3% Minocycline Foam;   Drug: 0.3% Adapalene Foam;   Other: Vehicle Foam
  Sponsor:   Foamix Ltd.
  Recruiting
• Pulmonary Hypertension Association Registry

  NCT04071327

  Conditions:   Pulmonary Arterial Hypertension;   Chronic Thromboembolic Pulmonary Hypertension;   Pulmonary Hypertension
  Intervention:  
  Sponsors:   Pulmonary Hypertension Association, Inc.;   University of Washington, the Collaborative Health Studies Coordinating Center
  Recruiting
• Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis.

  NCT04036435

  Condition:   Psoriasis
  Intervention:   Drug: BMS-986165
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study)

  NCT03593395

  Condition:   Sickle Cell Disease
  Interventions:   Other: Peer Mentoring [PM];   Other: Structured Education Based Transition Program STE
  Sponsors:   Ifeyinwa (Ify) Osunkwo MD MPH;   Patient-Centered Outcomes Research Institute
  Recruiting
• Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

  NCT03903822

  Condition:   Atopic Dermatitis
  Interventions:   Drug: PF-06700841;   Drug: Vehicle (Placebo)
  Sponsor:   Pfizer
  Recruiting
• Study in Subjects With Moderate Atopic Dermatitis

  NCT03859986

  Condition:   Atopic Dermatitis Eczema
  Interventions:   Drug: ALX-101 Gel Vehicle;   Drug: ALX-101 Gel 5%
  Sponsor:   Ralexar Therapeutics, Inc.
  Recruiting
• Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

  NCT03828019

  Condition:   Uveitis
  Interventions:   Biological: Adalimumab (ADA);   Drug: Conventional immunosuppression (CON)
  Sponsor:   JHSPH Center for Clinical Trials
  Recruiting
• Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

  NCT03824405

  Condition:   Atopic Dermatitis
  Interventions:   Drug: BTX 1204;   Drug: Vehicle
  Sponsor:   Botanix Pharmaceuticals
  Recruiting
• Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

  NCT03664739

  Condition:   Acne Vulgaris
  Interventions:   Drug: IDP-120 Gel;   Drug: IDp-120 Vehicle Gel
  Sponsor:   Bausch Health Americas, Inc.
  Recruiting
• A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

  NCT03635983

  Condition:   Melanoma
  Interventions:   Biological: NKTR-214;   Biological: Nivolumab
  Sponsors:   Bristol-Myers Squibb;   Nektar Therapeutics
  Recruiting
• Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

  NCT03435796

  Condition:   Neoplasms
  Intervention:   Genetic: Gene-modified (GM) T cell therapy
  Sponsor:   Celgene
  Recruiting
• Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus

  NCT03428945

  Condition:   Type1 Diabetes Mellitus
  Interventions:   Drug: Hydroxychloroquine;   Drug: Placebo
  Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Juvenile Diabetes Research Foundation
  Recruiting
• An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

  NCT03339297

  Conditions:   Graft-versus-host Disease;   Acute-graft-versus-host Disease
  Interventions:   Drug: Defibrotide;   Drug: Standard of Care
  Sponsor:   Jazz Pharmaceuticals
  Recruiting
• Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

  NCT03289273

  Condition:   Liver Neoplasms
  Intervention:   Drug: Regorafenib (Stivarga, BAY73-4506)
  Sponsor:   Bayer
  Recruiting
• A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients

  NCT03181932

  Conditions:   MRSA;   Cystic Fibrosis
  Interventions:   Drug: Vancomycin inhalation powder;   Drug: Placebo inhalation powder
  Sponsor:   Savara Inc.
  Recruiting
• A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

  NCT03105128

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab;   Drug: risankizumab IV;   Drug: risankizumab SC
  Sponsor:   AbbVie
  Recruiting
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

  NCT03104413

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab IV;   Drug: risankizumab SC;   Drug: risankizumab IV
  Sponsor:   AbbVie
  Recruiting
• Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment

  NCT03052517

  Condition:   Asthma
  Interventions:   Drug: QAW039 Dose 1;   Drug: QAW039 Dose 2;   Drug: Placebo
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• 3T MRI CIED Post-Approval Study

  NCT02969395

  Condition:   Cardiac Rhythm Disorder
  Intervention:  
  Sponsor:   Medtronic
  Recruiting
• A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)

  NCT02815891

  Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis
  Intervention:  
  Sponsor:   Target PharmaSolutions, Inc.
  Recruiting
• Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

  NCT02720744

  Conditions:   Excessive Daytime Sleepiness;   Cataplexy;   Narcolepsy
  Interventions:   Drug: Sodium Oxybate;   Drug: Placebo
  Sponsor:   Avadel
  Recruiting
• Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

  NCT02717507

  Condition:   Cancer Survivor
  Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

  NCT02435992

  Condition:   Ulcerative Colitis
  Interventions:   Drug: RPC1063;   Drug: Placebo
  Sponsor:   Celgene
  Recruiting
• OPsumit USers Registry

  NCT02126943

  Condition:   Pulmonary Arterial Hypertension
  Intervention:   Drug: Opsumit (macitentan)
  Sponsor:   Actelion
  Recruiting
• Product Surveillance Registry

  NCT01524276

  Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
  Intervention:  
  Sponsor:   Medtronic
  Recruiting
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

  NCT01442194

  Condition:   Multiple Sclerosis
  Interventions:   Drug: other disease-modifying therapy;   Drug: Fingolimod
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Neuropsychological and Behavioral Testing in Younger Patients With Cancer

  NCT00772200

  Conditions:   Childhood Malignant Neoplasm;   Cognitive Side Effects of Cancer Therapy
  Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• International Collaborative Gaucher Group (ICGG) Gaucher Registry

  NCT00358943

  Conditions:   Gaucher Disease;   Cerebroside Lipidosis Syndrome;   Glucocerebrosidase Deficiency Disease;   Glucosylceramide Beta-Glucosidase Deficiency Disease
  Intervention:  
  Sponsor:   Genzyme, a Sanofi Company
  Recruiting
• Pompe Disease Registry

  NCT00231400

  Conditions:   Glycogen Storage Disease Type II;   Pompe Disease
  Intervention:  
  Sponsor:   Genzyme, a Sanofi Company
  Recruiting
• Mucopolysaccharidosis I (MPS I) Registry

  NCT00144794

  Condition:   Mucopolysaccharidosis I (MPS I)
  Intervention:  
  Sponsor:   Genzyme, a Sanofi Company
  Recruiting